Wockhardt Ltd News

Pharma stocks zoom: Laurus Labs, Aurobindo hit new highs in trade

The BSE Healthcare index rallied over 1% in Monday's trade. Thus far in the financial year 2026-27, it outperformed the market by soaring 25%, against a near 4% rise in the BSE Sensex.

Nifty tech outlook signals caution, says Angel One; shares two stock ideas

The emerging technical structure highlights the need to exercise caution and warrants a clear strategy to avoid venturing into aggressive long trades.

Wockhardt Q1 results: Revenue rises 26% to ₹929 cr, profit at ₹107 cr

Pharmaceuticals firm Wockhardt Ltd on Monday reported a consolidated profit after tax of Rs 107 crore for the first quarter ended June 30, mainly due to strong revenue growth. The company had posted a consolidated net loss of Rs 108 crore in the corresponding period of the last fiscal, Wockhardt Ltd said in a regulatory filing. Its consolidated revenue from operations in the first quarter stood at Rs 929 crore against Rs 738 crore a year ago, it added. Total expenses in the quarter under review were higher at Rs 844 crore compared to Rs 770 crore in the year-ago period, it said.

Nifty Pharma extends rally, up 2%; Piramal Pharma, Laurus gain up to 10%

Analysts said that a combination of defensive buying, strong earnings visibility, export tailwinds, and sector rotation is driving the rally in pharma stocks.

Beyond Zaynich: Wockhardt bets on WCK 6777 as next blockbuster jab

Once-a-day injectable antibiotic aimed at treatment beyond hospitals through outpatient centres

Wockhardt targets 50% of revenue from novel drugs within five years

Wockhardt expects novel drugs to contribute over half its revenue within five years as it expands a differentiated antibiotic portfolio built through decades of R&D

Wockhardt eyes $1.5 bn peak sales from Zaynich, targets US launch by yr-end

Novel antibiotic to be launched in India around the same time; company to commercialise product on its own in US

Wockhardt soars 19%, zooms 75% in 1 month; what's driving pharma stock?

Wockhardt recently received USFDA approval for Zaynich (cefepime and zidebactam), a novel intravenous antibiotic for treating complicated urinary tract infections, including pyelonephritis, in adults.

Wockhardt hits all-time high on CDSCO approval for antibiotic Zaynich

The buying on the counter came after the company received approval from the CDSCO for the import and marketing of Zaynich Zidebactam/Cefepime

Breakout stocks: How to trade Ola, GMR Airports, Wockhardt? Analyst decodes

Mayank Jain, market analyst at Share.Market by PhonePe believes that the long-term trend for Ola Electric can change from 'Bearish to Bullish' if the stock manages to sustain above ₹40 consistently.

Stocks to buy: Wockhardt, TFCI, HBL Engg among analyst's top bets; check TP

Kunal Kamble, sr. technical research analyst at Bonanza, has recommended buying shares of Wockhardt, TFCI, and HBL Engineering today

Nifty Pharma hits 52-wk high; Wockhardt up 15%, Laurus, Lupin at new peaks

The Nifty Pharma index was quoting higher for the fifth straight trading day, surging 3.8 per cent during the period, as against 0.37 per cent gain in Nifty 50.

Wockhardt jumps 10% on posting Q4 profit turnaround; revenue up 30% YoY

In the March quarter (Q4FY26), Wockhardt posted net profit year-on-year (Y-o-Y) of ₹166 crore, as compared to a net loss of ₹25 crore a year ago